B/TWS/OT GGA ATT CTG TGG GAA GGT TTC GGC GGA GAT CCT TGC GAT CCT TGC ACC ACT TGG GTT GAC GCT ATC AGC ATG CGT ATG GGT TAC TAT GGT GAC TTT GTT TTC GAC CGC Comparison of our sequence data between codons 109 and 239 from two trachoma samples of serovar C with two urogenital specimens named Ca revealed only one divergence in VSII from the reference strain (see fig 2) . This difference could be monitored by enzyme Hinfl. On the other hand, two codon changes were observed between Ca and C that would modify amino acids in the region between VSII and VSIII and a third in VSIII (that could be monitored by loss of an MseI site present in the reference serovar C strain). At all four of these sites involving amino acid change the two specimens of urogenital origin (Ca) were similar to serovars A and H. Four nucleotide changes that would not modify the peptide sequence also distinguished the urogenital Ca from the trachoma serovar C samples. The two serovar C specimens of 2) . I and Ia.4 12 13 None of these sites were found in six urogenital Ca specimens tested including the two that were sequenced. One of the two amino acid modifications in VSI reported to distinguish urogenital C from trachoma C creates an SspI site7 which we observed in six of our Ca samples but not in four specimens from trachoma patients nor in reference C, J, H or A strains. Likewise the MboI site that could be predicted in VSIV from the published sequence of urogenital C7 or the J1 variant' was detected in six of our Ca specimens but not in four trachoma C samples, 19 urogenital J specimens nor in reference C, J, A or H strains. The BspEI site reported in VSIV in urogenital C but not in trachoma C7 was found both in six Ca and four of our trachoma C samples as well as in reference J and H, but not in reference A and C strains. Likewise RFLP in VSII was employed to distinguish B, Ba, D and E. The RsaI cleavage pattern specific of Ba was shared by all biotype Bb samples2 1011 and a unique BclI site in serovar D4 was also documented in all six biotype Db specimens tested.
Discussion
Comparison of the sequence of urogenital and trachoma specimens typed as serovar Ba or C by RFLP of amplified MOMP gene DNA indicated that although the VSI and VSII sequences were compatible with those of the reference Ba or C strains, several sequence changes outside VSI and II that would give rise to amino acid modifications distinguished the urogenital from the trachoma samples. Furthermore, urogenital isolates of serovar D could be separated into two groups on the basis of four different amino acid residues in the region of MOMP preceding VSI.
A very recent study from Winnipeg, Canada also demonstrated that urogenital Ba specimens were similar to trachoma Ba samples in VSI, II and IV.7 This same study did, however, identify differences at multiple sites in VSI, II and IV between their unique urogenital C sample and a reference C sample.7 Our two sequenced urogenital Ca specimens had identical VSII sequences to theirs whereas a urogenital sample termed J' by another group' had an identical VSIV to the Winnipeg group's urogenital C sample. Of the eight amino acid changes in VSI and IV distinguishing their urogenital sample from a trachoma strain,7 all six of our urogenital strains were shown by RFLP to possess at least three. The combined sequence analysis of their VSI, II and IV and our VSII, III and non-VS sequences indicated that urogenital Ca strains differed from reference trachoma C strains at 12 amino acids and at six amino acids from urogenital J strains. 
